Answers are grounded in this paper and cite their sources.
Newly emerging low-cost molecular assays and improved visual tests for cervical cancer screening call into question the role of visual inspection with acetic acid (VIA). VIA-based screening continues to offer a low-cost, single-visit approach for screening. However, VIA is highly rater-dependent and has problematic accuracy. RNA, DNA, and protein tests are now available. They offer greater accuracy and the option for self-sampling, but the testing kits are expensive. As these new options continue to improve, the time to move beyond VIA is fast approaching.
No takes yet. Share an insight, caveat, or question.
Silkensen et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: